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Purpose: Atrial fibrillation (AF) is one of the major risk factors for ischemic 
stroke, and 90% of thromboembolisms in these patients arise from the left atrial 
appendage (LAA). Recently, it has been documented that an LAA occlusion de-
vice (OD) is not inferior to warfarin therapy, and that it reduces mortality and risk 
of stroke in patients with AF. Materials and Methods: We implanted LAA-ODs 
in 5 Korean patients (all male, 59.8±7.3 years old) with long-standing persistent 
AF or permanent AF via a percutaneous trans-septal approach. Results: 1) The 
major reasons for LAA-OD implantation were high risk of recurrent stroke (80%), 
labile international neutralizing ratio with hemorrhage (60%), and 3/5 (60%) pa-
tients had a past history of failed cardioversion for rhythm control. 2) The mean 
LA size was 51.3±5.0 mm and LAA size was 25.1×30.1 mm. We implanted the 
LAA-OD (28.8±3.4 mm device) successfully in all 5 patients with no complica-
tions. 3) After eight weeks of anticoagulation, all patients switched from warfarin 
to anti-platelet agent after confirmation of successful LAA occlusion by trans-
esophageal echocardiography. Conclusion: We report on our early experience 
with LAA-OD deployment in patients with 1) persistent or permanent AF who 
cannot tolerate anticoagulation despite significant risk of ischemic stroke, or 2) re-
current stroke in patients who are unable to maintain sinus rhythm.
Key Words:   Atrial fibrillation, left atrial appendage, occlusion device, thrombo-
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INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia disease; its prevalence has 
been known to be 1-2% in the general population1 and is expected to rise.2 Due to 
inefficient atrial contractions and tissue factors, patients with AF have an annual 
6-10% risk of ischemic stroke, and the condition is responsible for 20% of isch-
emic strokes.3,4 In patients with non-valvular AF, the vast majority of intra-cardiac 
thrombus are generated in the left atrial appendage (LAA), according to post-mor-
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ing. Here, we report our very early experiences with LAA 
occlusion devices in Korean patients with AF. 
MATERIALS AND METHODS
　　　
Study population
This study included patients with persistent or permanent AF 
who had a significant risk of stroke or could not tolerate war-
farin therapy. Proper informed consent was obtained from all 
patients. The inclusion criteria were as follows: 1) permanent 
AF refractory to the electrical cardioversion, 2) persistent AF 
with failed maintenance of sinus rhythm with anti-arrhythmic 
drugs, 3) persistent AF and recurrent ischemic stroke despite 
proper anticoagulation, and 4) inability to tolerate warfarin 
due to adverse effects, labile INR, or recurrent hemorrhagic 
complications. We excluded patients with AF who were opti-
mal candidates for rhythm control strategy, anticoagulation, or 
who were at low risk for ischemic stroke. 
Structure of the LAA occlusion device
We used a WATCHMAN LAA occlusion device (Atritech, 
Plymouth, MN, USA) for LAA closure. The WATCHMAN 
device is composed of three parts as displayed in Fig. 1: 1) 
a delivery catheter (Fig. 1A, B and C), 2) a trans-septal 
tem and echocardiographic studies.5-7 Therefore, it has been 
established that appropriate anticoagulation is the best treat-
ment for stroke prevention with mortality benefits in pa-
tients with AF.8,9 However, anticoagulation with warfarin 
has many limitations, such as clinical under-utility,10,11 diffi-
culties in achieving optimal international neutralizing ratio 
(INR) values (64% in Rely, 63.8% in ACTIVE W),12,13 phar-
macokinetic interactions with other drugs, food, and a life-
style that requires regular blood test monitoring.14 Warfarin 
has an annual 3-5% risk of major bleeding and still has a 
1.4-1.6% risk of stroke during anticoagulation in patients 
with AF.12,13 The rate of intracerebral hemorrhage has been 
found to be between 0.1% and 0.6% during warfarin mono-
therapy in contemporary reports, but the major bleeding 
risk increases dramatically to 7.4-10.3% when warfarin is 
combined with aspirin and clopidogrel.15 In contrast to the 
warfarin strategy, surgeons have been reducing the risk of 
stroke by excising the LAA during mitral valve surgery or 
coronary artery bypass surgery.16,17 Recently, a PROTECT-
AF investigation revealed the percutaneous mechanical oc-
clusion of LAA not to be inferior to that of warfarin therapy.18 
Therefore, percutaneous closure of the LAA might provide an 
alternative strategy to chronic warfarin therapy for stroke 
prophylaxis in patients with AF, especially to those who can-
not tolerate warfarin or who have high risk of major bleed-
Fig. 1. LAA occlusion device. (A, B and C) Delivery catheter (A) including folded WATCHMAN device inside the catheter lumen (B) con-
nected to the deployment knob (C) and detachable by being unscrewed. (D) Trans-septal sheath has multiple radio-opaque marker bands 
that indicate the locations of delivery catheter and LAA ostium. (E and F) WATCHMAN device is unfolded by elastic recoil outside of de-
livery sheath (E) and remains in LAA after being detached from the delivery catheter (F). LAA, left atrial appendage.
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by intra-procedural TEE at the angles of 0°, 45°, 90°, and 
135° (Fig. 2A, B and C), and decided the optimal WATCH-
MAN device diameter, which was 8-20% larger in size 
than the maximal LAA ostial size. We performed a trans-
septal puncture with an 8 Fr Schwartz Left 1 sheath (St. 
Jude Medical Inc., Minnetonka, MN, USA) via the right 
femoral vein approach, and exchanged it with an 11 Fr 
trans-septal sheath (WATCHMAN Access system, Atritech, 
Plymouth, MN, USA) for the delivery catheter. Immediate-
ly after the trans-septal puncture, 150 U/kg of unfractionat-
ed heparin was administered intravenously, and activated 
clotting time (ACT) maintained at 300-350 sec. An LAA 
angiogram was taken at the right anterior oblique 45° with 
a pig-tail catheter (6Fr, A&A Medical Device Inc., Gyeong-
gi-do, Korea) inside the trans-septal sheath. The delivery 
catheter replaced a pig-tail catheter and was introduced into 
the trans-septal sheath in LAA. We lined up a distal radio-
opaque marker band on the trans-septal sheath with the de-
livery catheter marker band, and a proximal marker band 
on the trans-septal sheath with ostium of LAA. After con-
firming the correct position via injection of contrast media, 
we deployed the WATCHMAN device by withdrawing the 
whole system (trans-septal sheath and delivery catheter to-
gether) slowly at the fixed position of the deployment knob. 
The WATCHMAN device is a self-expanding nickel titani-
um (nitinol) frame structure with fixation barbs and a per-
meable polyester fabric cover. After confirming secure cap-
sheath (Fig. 1D), and 3) the WATCHMAN device (Fig. 1E 
and F). The trans-septal sheath guides the delivery catheter 
safely to the target site, and its depth in the LAA can be es-
timated under fluoroscopy by radio-opaque marker bands 
(Fig. 1D). The WATCHMAN device is folded inside the de-
livery catheter (Fig. 1B) and is designed to open like an um-
brella in the LAA via plastic recoil (Fig. 1E) when the opera-
tor pulls back the delivery catheter, maintaining a fixed 
position of the deployment knob (Fig. 1C). The WATCH-
MAN device can be detached from the delivery sheath by 
screwing out the deployment knob, and it remains in the 
LAA. The WATCHMAN device is a self-expandable nitinol 
frame covered with a polyethyl terephthalate fabric cap. The 
fabric cap works as a filter with 160 μm-sized micro-pores. 
Five different diameters of WATCHMAN devices are cur-
rently available, depending on the size of the LAA (21, 24, 
27, 30, and 33 mm). 
Implantation procedure of the LAA occlusion device
Before the procedure, LAA size and shape were evaluated 
by trans-esophageal echocardiography (TEE; iE33, Philips 
Medical System, Andover, MA, USA). Anticoagulation 
therapy was maintained on the date of procedure and con-
tinued at least for 8 weeks after successful implantation of 
the LAA occlusion device. The procedure was performed 
under general anesthesia and using intra-procedural TEE 
guidance. The ostial size and depth of LAA were measured 
Fig. 2. Intra-procedural TEE images before (A, B and C) and after (D) deployment of LAA occlusion device. Diameter of LAA ostium and 
depth of LAA were measured from 4 different angles of TEE images to determine the appropriate size of WATCHMAN device. (D) 
Successful deployment of device should be confirmed using a tug test and color Doppler. (E) RAO 45° fluoroscopic view after deployment 
of WATCHMAN device. (F) Eight week follow-up 3-D TEE showed complete sealing off of LAA by WATCHMAN device. TEE, trans-esoph-
ageal echocardiography; LAA, left atrial appendage; RAO, right anterior oblique.
A
D
B
E
C
F
Yung Ly Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 1   January 201286
ture of the device inside LAA via tug test and contrast 
injection, the device was disconnected from the deployment 
knob by being screwed out (Fig. 2C-F).
Post-procedural follow-up 
After deployment of the WATCHMAN device, we stopped 
heparin and removed the sheath when ACT <250 sec. The 
patients were discharged the next day and maintained aspi-
rin 100 mg and an optimal dose of warfarin (INR 2.0-3.0) 
for 8 weeks. TEE was repeated 8 weeks after the procedure, 
and we stopped warfarin and added clopidogrel 75 mg after 
confirming that there was no flow leakage between the 
WATCHMAN device and LAA. 
Data analysis 
We reviewed the reasons for deploying the LAA occlusion 
device, degrees of LA remodeling, CHADS2 score, shape 
and size of LAA, procedure time, adverse effects, and clini-
cal outcome.
 
RESULTS
 
We implanted LAA occlusion devices in 5 patients with AF, 
and the characteristics of these patients are summarized in 
Table 1. The mean age of the patients was 59.8±7.3 years 
old, and all of them were male. The major reasons for LAA 
occlusion device implantation were high risk of recurrent 
stroke (80%) and labile INR with hemorrhage (60%); 3/5 
(60%) patients had a history of failed cardioversion for 
rhythm control. The mean LA anterior posterior diameter 
was 51.3±5.0 mm and LAA size was 25.1×30.1 mm. We 
implanted LAA occlusion devices (28.8±3.4 mm device) 
successfully in all 5 patients without complications. The 
mean procedure time was 72.8±10.1 min. After 8 weeks of 
anticoagulation, all patients switched from warfarin to anti-
platelet agent after confirmation of successful LAA occlu-
sion by trans-esophageal echocardiography.  
Case 1 
A 53-year-old male taxi driver came to the emergency room 
after suddenly developing right-side motor weakness. His 
electrocardiography showed low voltage QRS with AF, and 
brain computed tomography revealed an embolic cerebral 
infarction in the region of the left side middle cerebral ar-
tery. He had a history of persistent AF lasting longer than 4 
years and initially presented with symptomatic pericardial Ta
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complications (Fig. 2D and F). Because the device was 
well-fitted within the LAA (Fig. 2E) and there was no flow 
leakage between the LAA and the WATCHMAN device, 
we stopped warfarin and switched to clopidogrel.
Case 2 
The second case was a 67-year-old male patient with hy-
pertension and diabetes who had experienced an embolic 
stroke 3 years prior. Unfortunately, cerebral hemorrhage 
and optic nerve damage had occurred related to an adverse 
event of anticoagulation 2 years prior. Therefore, we switched 
from warfarin to aspirin and clopidogrel. However, the pa-
tient had another ischemic stroke again 7 months after start-
ing the antiplatelet agent in place of warfarin. We decided to 
deploy the LAA occlusion device due to his recurrent strokes 
and high risk of bleeding with anticoagulation. The WATCH-
MAN device implantation was successful and we main-
tained warfarin for 8 weeks with very careful INR monitor-
ing, and finally stopped anticoagulation after confirmation 
of no leakage with TEE. 
Cases 3 and 4
Cases 3 and 4 had recurrent ischemic strokes and a large 
middle cerebral artery infarction, respectively (Table 1). The 
patients did not want continuous warfarin therapy because 
they had frequent minor bleeding despite optimal INR. 
Rhythm control with electrical cardioversion was attempted 
in both patients, but AF recurred within a week despite anti-
arrhythmic drugs. Therefore, we successfully deployed a 
effusion. At that time, we could not find any pathology for 
pericardial effusion except for mediastinal lymphadenopathy 
and high adenosine deaminase level in the pericardial fluid. 
The mediastinal lymph node biopsy results indicated reac-
tive hyperplasia. Anti-tuberculous medication was pre-
scribed for one year under the impression that the patient 
had tuberculous pericarditis. However, he still had a mild 
degree of pericardial effusion, despite medication. His LA 
anterior posterior diameter measured by trans-thoracic echo-
cardiography was 50.0 mm and his left ventricular ejection 
fraction was within the normal limits. To prevent ischemic 
stroke, anti-coagulation was maintained, but it was very hard 
to keep INR at the optimal level, despite strict drug and diet 
control. INR levels fluctuated remarkably, and the patient 
came to the emergency room several times due to severe 
bruising (Fig. 3). Because of labile INR with warfarin, we 
attempted rhythm control using cardioversion, but AF re-
curred very soon after cardioversion. We stopped warfarin 
and switched to clopidogrel; his CHADS2 score was 1 at that 
time. Unfortunately, this patient had an embolic stroke 9 
months after switching to an anti-platelet agent. Fig. 3 dis-
plays the warfarin dosage and INR values. When he started 
anti-tuberculous medication, his INR level was sub-optimal 
despite a high warfarin dosage, but it rose after stopping ri-
fampin and increased rather drastically, even with 0.5 mg of 
warfarin. After an ischemic stroke, the neurologist pre-
scribed low-dosage warfarin, but the INR value increased to 
higher than 8.0. Therefore, we decided to implant an LAA 
closing device, and the procedure was successful, with no 
Fig. 3. Warfarin dosage and INR values of case 1. INR values were extremely labile, and ischemic stroke occurred 9 months after switch-
ing to clopidogrel. INR, international neutralizing ratio; MCA, middle cerebral artery.
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percutaneous epicardial LAA suture ligation approach was 
also tested for pre-clinical feasibility.22 Recently, the PRO-
TECT-AF trial, the largest-scale study to date, with 707 pa-
tients, showed that hemorrhagic stroke occurred less often 
with the WATCHMAN device than with warfarin treatment; 
stroke and all-cause mortality outcomes were non-inferior.18 
The inclusion criteria were: patients aged >18 years old 
with paroxysmal, persistent, or permanent non-valvular AF 
and CHADS2 score ≥1. In the WATCHMAN group, the 
procedure success rate was 88%; 85% of them had stopped 
warfarin after 45 days and 92% after six months, if TEE 
showed residual peri-device flow jet <5 mm in width. There-
fore, the WATCHMAN device is ideally indicated for pa-
tients with persistent or permanent AF who cannot tolerate 
anticoagulation despite a significant risk of ischemic or re-
current stroke, and who are unable to maintain sinus rhythm. 
If anticoagulation is contraindicated, the patient is not can-
didate for the WATCHMAN device, as the procedure requires 
that patients undergo anticoagulation for several weeks af-
ter deployment. It is not clear whether an LAA occlusion 
device can replace warfarin or rhythm control strategy in 
patients with AF; further study with a longer follow-up pe-
riod is warranted. 
Potential complications of LAA occlusion device
Although the PROTECT-AF trial showed the non-inferiority 
of the LAA occlusion device compared to warfarin (>99.9% 
with regard to any kind of stroke, cardiovascular or unex-
plained death, or systemic embolism within up to 3 years), 
procedure-related adverse events should be accounted for, 
such as cardiac tamponade (4.8%), device embolization or 
dislodgement (0.4%), procedure-related stroke (mostly air 
embolism 1.1%), or sepsis.18 However, Reddy, et al.23 recent-
ly reported that such adverse events were dependent on the 
level of experience of the operator. The subsequent registry 
after the PROTECT AF trial showed a significantly im-
proved success rate of implantation (91.3% to 95.0%), and 
reduced procedure time as well as the occurrence of proce-
dure-related adverse events (6.5% to 3.7%). The procedure-
related stroke rate was reduced to 0%. 
Unsolved issue
Long-term safety data for the WATCHMAN device are still 
unavailable and need to be taken into account for clinical 
consensus. Complex aortic plaque on the descending aorta 
is an independent risk factor for stroke in AF24 and the de-
gree of electroanatomical remodeling of LA may affect the 
WATCHMAN device in each patient. The shape of the LAA 
in patient #4 was of the multi-lobulated Broccoli type, with 
a broad base and short length. In this type of LAA, the de-
vice was easily shifted or tilted to the dominant lobe of the 
LAA. Therefore, we repeated deployment and recapture of 
the device several times, and finally implanted a 30.0 mm 
sized device at the optimal site without complication. The 
eight week follow-up TEE showed successful implantation 
of the device in both patients, and so warfarin was switched 
to anti-platelet agent. 
Case 5
Case #5 was a 67-year-old patient with permanent AF. Al-
though his CHADS2 score was 1, his LA diameter was 60.0 
mm and TEE showed severe spontaneous echo contrast. 
His INR value was very unstable and he experienced fre-
quent purpura on his skin. Therefore, we successfully de-
ployed the LAA occlusion device, and switched from war-
farin to clopidogrel 8 weeks after implantation.
DISCUSSION
We report five cases of persistent or permanent AF that were 
successfully treated with LAA occlusion devices. None of 
the patients had been able to tolerate anticoagulation, de-
spite significant risk of stroke because of labile INR or ad-
verse hemorrhagic events. Three of them failed to maintain 
rhythm control after electrical cardioversion, and cardiover-
sion was not attempted in two of them due to a huge atrium 
or to a high risk of bleeding with anticoagulation. Therefore, 
an LAA occlusion device might be considered for patients 
with persistent or permanent AF who cannot tolerate anti-
coagulation and cannot maintain sinus rhythm.
Efficacy of LAA closure and ideal indications  
in patients with AF
It is well established that more than 90% of atrial thrombi 
originate from the LAA,19 and the surgical MAZE proce-
dure typically includes occlusion of the LAA. Current evi-
dence regarding embolic risk reduction with percutaneous 
LAA occlusion is encouraging. There have been several tri-
als evaluating less invasive LAA closure devices, such as 
thoracoscopic extracardiac obliteratin of LAA (LAPTO-
NI)20 or percutaneous LAA transcatheter occlusion (PLAA-
TO device)21 in order to prevent stroke in patients with AF, 
but the clinical outcomes were only partial successful. The 
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binder M, et al. Percutaneous closure of the left atrial appendage 
risk and event of stroke in patients with AF. The current 
guidelines recommend switching from warfarin to dural an-
tiplatelet therapy 6-8 weeks after successful deployment of 
the LAA occlusion device.18 However, the risk of bleeding 
with dual anti-platelet therapy should be considered even 
after deployment of the LAA occlusion device. Theoretical-
ly, complete rhythm control might be better than an LAA 
occlusion device in terms of etiology of ischemic stroke and 
hemodynamics. Therefore, LAA occlusion devices should 
be compared with catheter ablation of AF or newly devel-
oped effective anti-arrhythmic drugs.25-27 Comparisons with 
direct thrombin or coagulation factor Xa inhibitors will be 
required.28 The clinical efficacy of newly designed LAA 
closure devices, such as the Amplatzer cardiac plug, need 
to be evaluated in a large randomized trial.29 
In conclusion, here we report our early experience with 
LAA-OD deployment in patients with 1) persistent or per-
manent AF who cannot tolerate anticoagulation despite sig-
nificant risk of ischemic stroke or 2) recurrent stroke and 
inability to maintain sinus rhythm. 
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